



## ABOUT ARRAY BIOPHARMA



Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions. Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib, binimetinib, ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics).

## IN THE NEWS



COLUMBUS Phase 3: Encorafenib and binimetinib mOS 33.6 months

BEACON CRC Safety Lead-in at 2018 ASCO GI: Triple combination mPFS 8.0 months; 48% ORR, including 3 CRs

## BY THE NUMBERS



NASDAQ	<b>ARRY</b>
Market Capitalization	<b>&gt;\$3B</b>
Staff	<b>250</b>
Cash (12/31/17)	<b>\$420.3M</b>
Headquarters	<b>Boulder, CO</b>

www.arraybiopharma.com  
 Info@arraybiopharma.com  
 303.381.6600  
 3200 Walnut Street  
 Boulder, Colorado 80301

## Path to Commercialization & Upcoming Catalysts

### Significant Pipeline Milestones Achieved...

### ... Important Value-Drivers

<b>NEAR-TERM COMMERCIAL / BRAF-MUTANT MELANOMA</b> 	<b>NDAs &amp; MAAs for BRAFm melanoma under regulatory review</b> <ul style="list-style-type: none"> <li>Secondary endpoint: mOS 33.6 months</li> <li>Phase 3 met primary endpoint: mPFS 14.9 months</li> </ul>	Global regulatory reviews FDA PDUFA June 30, 2018; FDA not currently planning to hold an ODAC
<b>PHASE 3 / BRAF-MUTANT CRC</b> 	<b>Promising activity in safety lead-in reported at ASCO GI 2018</b> <ul style="list-style-type: none"> <li>Triple combination well-tolerated</li> <li>8.0 months mPFS; 48% confirmed ORR, including 3 CRs</li> </ul>	Randomized portion of trial actively enrolling
<b>I/O COLLABORATIONS</b> 	<b>BMS collaboration</b> Binimetinib + nivolumab +/- ipilimumab in patients with RASm MSS CRC	Trial active
	<b>Merck-sponsored collaboration</b> Binimetinib + pembrolizumab +/- FOLFOX or FOLFIRI in patients with MSS CRC	Trial active
	<b>Pfizer-sponsored collaboration</b> Binimetinib + avelumab +/- talazoparib in patients with cancer	Trial to begin 3Q2018

### COST SHARING

Novartis reimbursement totaled \$88.5M past 12 reported months  
 BEACON CRC co-funding: Pierre Fabre (40%), Ono Pharmaceuticals (milestone payments), Merck KGaA (Erbtix supply)

## Strategy

We are building a fully integrated, commercial-stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer. We intend to accomplish this through the following strategies:



**Invent targeted small molecule drugs** that are either first-in-class or second generation drugs that have little or no competition, or demonstrate a competitive advantage over drugs currently on the market or in clinical development.



**Selectively develop and commercialize our drugs** to maximize their overall value. As our first drug nears approval, we are building a U.S.-based, therapeutically focused sales force to commercialize or co-promote drugs we wholly own or for which we retain development rights in certain geographic areas.



**Implement a partnering strategy** in which we retain U.S. commercial and/or co-promotion rights for drugs that can be distributed through a therapeutically specialized sales force and partner select early-stage programs for continued research and development to receive research funding plus significant milestone payments and royalties.

## Partnerships

ONO PHARMACEUTICAL CO., LTD.

AstraZeneca

Pierre Fabre

AMGEN

Genentech  
 A Member of the Roche Group

AsahiKASEI

LOXO  
 ONCOLOGY